TP53 and neoplasm: Large-scale studies of tumor tissue (Ross et al. and Robertson et al.)and ctDNA (Agarwal et al., Grivas et al., and Shohdy et al.)found targetable mutations in urothelial cancer at similar rates, including TP53 (48–64%), PIK3CA (14–24.2%), FGFR3 (10–21%), and ERBB2 (10–19.4%) [96,105,106,111,112].